1
|
Ayyalasomayajula R, Cudic M. Targeting Siglec-Sialylated MUC1 Immune Axis in Cancer. Cancers (Basel) 2024; 16:1334. [PMID: 38611013 PMCID: PMC11011055 DOI: 10.3390/cancers16071334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2023] [Revised: 03/12/2024] [Accepted: 03/27/2024] [Indexed: 04/14/2024] Open
Abstract
Siglecs play a key role in mediating cell-cell interactions via the recognition of different sialylated glycoconjugates, including tumor-associated MUC1, which can lead to the activation or inhibition of the immune response. The activation occurs through the signaling of Siglecs with the cytoplasmic immunoreceptor tyrosine-based activation motif (ITAM)-containing proteins, while the inhibition signal is a result of the interaction of intracellular immunoreceptor tyrosine-based inhibition motif (ITIM)-bearing receptors. The interaction of tumor-associated MUC1 sialylated glycans with Siglecs via ITIM motifs decreases antitumor immunity. Consequently, these interactions are expected to play a key role in tumor evasion. Efforts to modulate the response of immune cells by blocking the immune-suppressive effects of inhibitory Siglecs, driving immune-activating Siglecs, and/or altering the synthesis and expression of the sialic acid glycocalyx are new therapeutic strategies deserving further investigation. We will highlight the role of Siglec's family receptors in immune evasion through interactions with glycan ligands in their natural context, presented on the protein such as MUC1, factors affecting their fine binding specificities, such as the role of multivalency either at the ligand or receptor side, their spatial organization, and finally the current and future therapeutic interventions targeting the Siglec-sialylated MUC1 immune axis in cancer.
Collapse
Affiliation(s)
| | - Mare Cudic
- Department of Chemistry and Biochemistry, Florida Atlantic University, 777 Glades Rd., Boca Raton, FL 33431, USA;
| |
Collapse
|
2
|
Bermejo IA, Guerreiro A, Eguskiza A, Martínez-Sáez N, Lazaris FS, Asín A, Somovilla VJ, Compañón I, Raju TK, Tadic S, Garrido P, García-Sanmartín J, Mangini V, Grosso AS, Marcelo F, Avenoza A, Busto JH, García-Martín F, Hurtado-Guerrero R, Peregrina JM, Bernardes GJL, Martínez A, Fiammengo R, Corzana F. Structure-Guided Approach for the Development of MUC1-Glycopeptide-Based Cancer Vaccines with Predictable Responses. JACS AU 2024; 4:150-163. [PMID: 38274250 PMCID: PMC10807005 DOI: 10.1021/jacsau.3c00587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/30/2023] [Revised: 11/08/2023] [Accepted: 11/09/2023] [Indexed: 01/27/2024]
Abstract
Mucin-1 (MUC1) glycopeptides are exceptional candidates for potential cancer vaccines. However, their autoantigenic nature often results in a weak immune response. To overcome this drawback, we carefully engineered synthetic antigens with precise chemical modifications. To be effective and stimulate an anti-MUC1 response, artificial antigens must mimic the conformational dynamics of natural antigens in solution and have an equivalent or higher binding affinity to anti-MUC1 antibodies than their natural counterparts. As a proof of concept, we have developed a glycopeptide that contains noncanonical amino acid (2S,3R)-3-hydroxynorvaline. The unnatural antigen fulfills these two properties and effectively mimics the threonine-derived antigen. On the one hand, conformational analysis in water shows that this surrogate explores a landscape similar to that of the natural variant. On the other hand, the presence of an additional methylene group in the side chain of this analog compared to the threonine residue enhances a CH/π interaction in the antigen/antibody complex. Despite an enthalpy-entropy balance, this synthetic glycopeptide has a binding affinity slightly higher than that of its natural counterpart. When conjugated with gold nanoparticles, the vaccine candidate stimulates the formation of specific anti-MUC1 IgG antibodies in mice and shows efficacy comparable to that of the natural derivative. The antibodies also exhibit cross-reactivity to selectively target, for example, human breast cancer cells. This investigation relied on numerous analytical (e.g., NMR spectroscopy and X-ray crystallography) and biophysical techniques and molecular dynamics simulations to characterize the antigen-antibody interactions. This workflow streamlines the synthetic process, saves time, and reduces the need for extensive, animal-intensive immunization procedures. These advances underscore the promise of structure-based rational design in the advance of cancer vaccine development.
Collapse
Affiliation(s)
- Iris A. Bermejo
- Department
of Chemistry and Instituto de Investigación en Química
de la Universidad de La Rioja (IQUR), Universidad
de La Rioja, Logroño 26006, Spain
| | - Ana Guerreiro
- Instituto
de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa 1649-028, Portugal
| | - Ander Eguskiza
- Department
of Biotechnology, University of Verona, Verona 37134, Italy
| | - Nuria Martínez-Sáez
- Department
of Chemistry and Instituto de Investigación en Química
de la Universidad de La Rioja (IQUR), Universidad
de La Rioja, Logroño 26006, Spain
- Departamento
de Tecnología y Química Farmacéuticas, Universidad de Navarra, Pamplona 31008, Spain
| | - Foivos S. Lazaris
- Department
of Chemistry and Instituto de Investigación en Química
de la Universidad de La Rioja (IQUR), Universidad
de La Rioja, Logroño 26006, Spain
| | - Alicia Asín
- Department
of Chemistry and Instituto de Investigación en Química
de la Universidad de La Rioja (IQUR), Universidad
de La Rioja, Logroño 26006, Spain
| | - Víctor J. Somovilla
- Department
of Chemistry and Instituto de Investigación en Química
de la Universidad de La Rioja (IQUR), Universidad
de La Rioja, Logroño 26006, Spain
| | - Ismael Compañón
- Department
of Chemistry and Instituto de Investigación en Química
de la Universidad de La Rioja (IQUR), Universidad
de La Rioja, Logroño 26006, Spain
| | - Tom K. Raju
- Angiogenesis
Group, Oncology Area, Center for Biomedical
Research of La Rioja (CIBIR), Logroño 26006, Spain
| | - Srdan Tadic
- Angiogenesis
Group, Oncology Area, Center for Biomedical
Research of La Rioja (CIBIR), Logroño 26006, Spain
| | - Pablo Garrido
- Angiogenesis
Group, Oncology Area, Center for Biomedical
Research of La Rioja (CIBIR), Logroño 26006, Spain
| | - Josune García-Sanmartín
- Angiogenesis
Group, Oncology Area, Center for Biomedical
Research of La Rioja (CIBIR), Logroño 26006, Spain
| | - Vincenzo Mangini
- Center
for
Biomolecular Nanotechnologies@UniLe, Istituto
Italiano di Tecnologia (IIT), Arnesano, Lecce 73010, Italy
| | - Ana S. Grosso
- Applied
Molecular Biosciences Unit UCIBIO, Department of Chemistry, NOVA School of Science and Technology, Caparica 2829-516, Portugal
- Associate
Laboratory i4HB - Institute for Health and Bioeconomy, NOVA School of Science and Technology, Caparica 2829-516, Portugal
| | - Filipa Marcelo
- Applied
Molecular Biosciences Unit UCIBIO, Department of Chemistry, NOVA School of Science and Technology, Caparica 2829-516, Portugal
- Associate
Laboratory i4HB - Institute for Health and Bioeconomy, NOVA School of Science and Technology, Caparica 2829-516, Portugal
| | - Alberto Avenoza
- Department
of Chemistry and Instituto de Investigación en Química
de la Universidad de La Rioja (IQUR), Universidad
de La Rioja, Logroño 26006, Spain
| | - Jesús H. Busto
- Department
of Chemistry and Instituto de Investigación en Química
de la Universidad de La Rioja (IQUR), Universidad
de La Rioja, Logroño 26006, Spain
| | - Fayna García-Martín
- Department
of Chemistry and Instituto de Investigación en Química
de la Universidad de La Rioja (IQUR), Universidad
de La Rioja, Logroño 26006, Spain
| | - Ramón Hurtado-Guerrero
- Institute
of Biocomputation and Physics of Complex Systems, University of Zaragoza, Zaragoza 50018, Spain
- Copenhagen
Center for Glycomics, Department of Cellular and Molecular Medicine,
Faculty of Health Sciences, University of
Copenhagen, Copenhagen 2200, Denmark
- Fundación
ARAID, Zaragoza 50018, Spain
| | - Jesús M. Peregrina
- Department
of Chemistry and Instituto de Investigación en Química
de la Universidad de La Rioja (IQUR), Universidad
de La Rioja, Logroño 26006, Spain
| | - Gonçalo J. L. Bernardes
- Instituto
de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa 1649-028, Portugal
- Yusuf
Hamied Department of Chemistry, University
of Cambridge, Cambridge CB2 1EW, U.K.
| | - Alfredo Martínez
- Angiogenesis
Group, Oncology Area, Center for Biomedical
Research of La Rioja (CIBIR), Logroño 26006, Spain
| | - Roberto Fiammengo
- Department
of Biotechnology, University of Verona, Verona 37134, Italy
- Center
for
Biomolecular Nanotechnologies@UniLe, Istituto
Italiano di Tecnologia (IIT), Arnesano, Lecce 73010, Italy
| | - Francisco Corzana
- Department
of Chemistry and Instituto de Investigación en Química
de la Universidad de La Rioja (IQUR), Universidad
de La Rioja, Logroño 26006, Spain
| |
Collapse
|
3
|
Wakui H, Yokoi Y, Horidome C, Ose T, Yao M, Tanaka Y, Hinou H, Nishimura SI. Structural and molecular insight into antibody recognition of dynamic neoepitopes in membrane tethered MUC1 of pancreatic cancer cells and secreted exosomes. RSC Chem Biol 2023; 4:564-572. [PMID: 37547453 PMCID: PMC10398351 DOI: 10.1039/d3cb00036b] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Accepted: 05/19/2023] [Indexed: 08/08/2023] Open
Abstract
Pancreatic cancer is highly metastatic and has poor prognosis, mainly due to delayed detection, often after metastasis has occurred. A novel method to enable early detection and disease intervention is strongly needed. Here we unveil for the first time that pancreatic cancer cells (PANC-1) and secreted exosomes express MUC1 bearing cancer-relevant dynamic epitopes recognized specifically by an anti-MUC1 antibody (SN-131), which binds specifically core 1 but not core 2 type O-glycans found in normal cells. Comprehensive assessment of the essential epitope for SN-131 indicates that PANC-1 cells produce dominantly MUC1 with aberrant O-glycoforms such as Tn, T, and sialyl T (ST) antigens. Importantly, SN-131 showed the highest affinity with MUC1 bearing ST antigen at the immunodominant DTR motif (KD = 1.58 nM) independent of the glycosylation states of other Ser/Thr residues in the MUC1 tandem repeats. The X-ray structure revealed that SN-131 interacts directly with Neu5Ac and root GalNAc of the ST antigen in addition to the proximal peptide region. Our results demonstrate that targeting O-glycosylated "dynamic neoepitopes" found in the membrane-tethered MUC1 is a promising therapeutic strategy for improving the treatment outcome of patients with pancreatic cancer.
Collapse
Affiliation(s)
- Hajime Wakui
- Field of Drug Discovery Research, Faculty of Advanced Life Science, and Graduate School of Life Science, Hokkaido University N21 W11 Kita-ku Sapporo 001-0021 Japan
| | - Yasuhiro Yokoi
- Field of Drug Discovery Research, Faculty of Advanced Life Science, and Graduate School of Life Science, Hokkaido University N21 W11 Kita-ku Sapporo 001-0021 Japan
| | - Chieko Horidome
- Field of Drug Discovery Research, Faculty of Advanced Life Science, and Graduate School of Life Science, Hokkaido University N21 W11 Kita-ku Sapporo 001-0021 Japan
| | - Toyoyuki Ose
- Field of X-ray Structural Biology, Faculty of Advanced Life Science, and Graduate School of Life Science, Hokkaido University N10 W8 Kita-ku Sapporo 060-0810 Japan
| | - Min Yao
- Field of X-ray Structural Biology, Faculty of Advanced Life Science, and Graduate School of Life Science, Hokkaido University N10 W8 Kita-ku Sapporo 060-0810 Japan
| | - Yoshikazu Tanaka
- Graduate School of Life Sciences, Tohoku University 2-1-1 Katahira Aoba-ku Sendai 980-8577 Japan
| | - Hiroshi Hinou
- Field of Drug Discovery Research, Faculty of Advanced Life Science, and Graduate School of Life Science, Hokkaido University N21 W11 Kita-ku Sapporo 001-0021 Japan
| | - Shin-Ichiro Nishimura
- Field of Drug Discovery Research, Faculty of Advanced Life Science, and Graduate School of Life Science, Hokkaido University N21 W11 Kita-ku Sapporo 001-0021 Japan
| |
Collapse
|
4
|
Pifferi C, Aguinagalde L, Ruiz-de-Angulo A, Sacristán N, Baschirotto PT, Poveda A, Jiménez-Barbero J, Anguita J, Fernández-Tejada A. Development of synthetic, self-adjuvanting, and self-assembling anticancer vaccines based on a minimal saponin adjuvant and the tumor-associated MUC1 antigen. Chem Sci 2023; 14:3501-3513. [PMID: 37006677 PMCID: PMC10055764 DOI: 10.1039/d2sc05639a] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Accepted: 03/01/2023] [Indexed: 03/05/2023] Open
Abstract
The overexpression of aberrantly glycosylated tumor-associated mucin-1 (TA-MUC1) in human cancers makes it a major target for the development of anticancer vaccines derived from synthetic MUC1-(glyco)peptide antigens. However, glycopeptide-based subunit vaccines are weakly immunogenic, requiring adjuvants and/or additional immunopotentiating approaches to generate optimal immune responses. Among these strategies, unimolecular self-adjuvanting vaccine constructs that do not need coadministration of adjuvants or conjugation to carrier proteins emerge as a promising but still underexploited approach. Herein, we report the design, synthesis, immune-evaluation in mice, and NMR studies of new, self-adjuvanting and self-assembling vaccines based on our QS-21-derived minimal adjuvant platform covalently linked to TA-MUC1-(glyco)peptide antigens and a peptide helper T-cell epitope. We have developed a modular, chemoselective strategy that harnesses two distal attachment points on the saponin adjuvant to conjugate the respective components in unprotected form and high yields via orthogonal ligations. In mice, only tri-component candidates but not unconjugated or di-component combinations induced significant TA-MUC1-specific IgG antibodies able to recognize the TA-MUC1 on cancer cells. NMR studies revealed the formation of self-assembled aggregates, in which the more hydrophilic TA-MUC1 moiety gets exposed to the solvent, favoring B-cell recognition. While dilution of the di-component saponin-(Tn)MUC1 constructs resulted in partial aggregate disruption, this was not observed for the more stably-organized tri-component candidates. This higher structural stability in solution correlates with their increased immunogenicity and suggests a longer half-life of the construct in physiological media, which together with the enhanced antigen multivalent presentation enabled by the particulate self-assembly, points to this self-adjuvanting tri-component vaccine as a promising synthetic candidate for further development.
Collapse
Affiliation(s)
- Carlo Pifferi
- Chemical Immunology Laboratory, Center for Cooperative Research in Biosciences (CIC BioGUNE), Basque Research and Technology Alliance (BRTA) Biscay Technology Park, Building 801A 48160 Derio Spain
| | - Leire Aguinagalde
- Chemical Immunology Laboratory, Center for Cooperative Research in Biosciences (CIC BioGUNE), Basque Research and Technology Alliance (BRTA) Biscay Technology Park, Building 801A 48160 Derio Spain
| | - Ane Ruiz-de-Angulo
- Chemical Immunology Laboratory, Center for Cooperative Research in Biosciences (CIC BioGUNE), Basque Research and Technology Alliance (BRTA) Biscay Technology Park, Building 801A 48160 Derio Spain
| | - Nagore Sacristán
- Chemical Immunology Laboratory, Center for Cooperative Research in Biosciences (CIC BioGUNE), Basque Research and Technology Alliance (BRTA) Biscay Technology Park, Building 801A 48160 Derio Spain
| | - Priscila Tonon Baschirotto
- Chemical Immunology Laboratory, Center for Cooperative Research in Biosciences (CIC BioGUNE), Basque Research and Technology Alliance (BRTA) Biscay Technology Park, Building 801A 48160 Derio Spain
| | - Ana Poveda
- Chemical Glycobiology Laboratory, CIC BioGUNE, BRTA Spain
| | - Jesús Jiménez-Barbero
- Chemical Glycobiology Laboratory, CIC BioGUNE, BRTA Spain
- Ikerbasque, Basque Foundation for Science Maria Diaz de Haro 13 48009 Bilbao Spain
- Department of Organic Chemistry II, Faculty of Science & Technology, University of the Basque Country 48940 Leioa Spain
- Centro de Investigación Biomédica En Red de Enfermedades Respiratorias Av. Monforte de Lemos, 3-5 28029 Madrid Spain
| | - Juan Anguita
- Ikerbasque, Basque Foundation for Science Maria Diaz de Haro 13 48009 Bilbao Spain
- Inflammation and Macrophage Plasticity Laboratory, CIC BioGUNE, BRTA Spain
| | - Alberto Fernández-Tejada
- Chemical Immunology Laboratory, Center for Cooperative Research in Biosciences (CIC BioGUNE), Basque Research and Technology Alliance (BRTA) Biscay Technology Park, Building 801A 48160 Derio Spain
- Ikerbasque, Basque Foundation for Science Maria Diaz de Haro 13 48009 Bilbao Spain
| |
Collapse
|
5
|
Kohout VR, Wardzala CL, Kramer JR. Synthesis and biomedical applications of mucin mimic materials. Adv Drug Deliv Rev 2022; 191:114540. [PMID: 36228896 PMCID: PMC10066857 DOI: 10.1016/j.addr.2022.114540] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2022] [Revised: 08/17/2022] [Accepted: 09/13/2022] [Indexed: 02/09/2023]
Abstract
Mucin glycoproteins are the major component of mucus and coat epithelial cell surfaces forming the glycocalyx. The glycocalyx and mucus are involved in the transport of nutrients, drugs, gases, and pathogens toward the cell surface. Mucins are also involved in diverse diseases such as cystic fibrosis and cancer. Due to inherent heterogeneity in native mucin structure, many synthetic materials have been designed to probe mucin chemistry, biology, and physics. Such materials include various glycopolymers, low molecular weight glycopeptides, glycopolypeptides, polysaccharides, and polysaccharide-protein conjugates. This review highlights advances in the area of design and synthesis of mucin mimic materials, and their biomedical applications in glycan binding, epithelial models of infection, therapeutic delivery, vaccine formulation, and beyond.
Collapse
Affiliation(s)
- Victoria R Kohout
- Department of Biomedical Engineering, University of Utah, 36 S. Wasatch Dr., Salt Lake City, UT 84112, USA
| | - Casia L Wardzala
- Department of Biomedical Engineering, University of Utah, 36 S. Wasatch Dr., Salt Lake City, UT 84112, USA
| | - Jessica R Kramer
- Department of Biomedical Engineering, University of Utah, 36 S. Wasatch Dr., Salt Lake City, UT 84112, USA.
| |
Collapse
|
6
|
Exploring the In situ pairing of human galectins toward synthetic O-mannosylated core M1 glycopeptides of α-dystroglycan. Sci Rep 2022; 12:17800. [PMID: 36274065 PMCID: PMC9588787 DOI: 10.1038/s41598-022-22758-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2022] [Accepted: 10/19/2022] [Indexed: 01/19/2023] Open
Abstract
Dystroglycan (DG), which constitutes a part of the dystrophin-glycoprotein complex, connects the extracellular matrix to the cytoskeleton. The matriglycans presented by the extracellular α-DG serve as a contact point with extracellular matrix proteins (ECM) containing laminin G-like domains, providing cellular stability. However, it remains unknown whether core M1 (GlcNAcβ1-2Man) structures can serve as ligands among the various O-Mannosylated glycans. Therefore, based on the presence of N-acetylLactosamine (LacNAc) in this glycan following the core extension, the binding interactions with adhesion/growth-regulatory galectins were explored. To elucidate this process, the interaction between galectin (Gal)-1, -3, -4 and -9 with α-DG fragment 372TRGAIIQTPTLGPIQPTRV390 core M1-based glycopeptide library were profiled, using glycan microarray and nuclear magnetic resonance studies. The binding of galectins was revealed irrespective of its modular architecture, adding galectins to the list of possible binding partners of α-DG core M1 glycoconjugates by cis-binding (via peptide- and carbohydrate-protein interactions), which can be abrogated by α2,3-sialylation of the LacNAc units. The LacNAc-terminated α-DG glycopeptide interact simultaneously with both the S- and F-faces of Gal-1, thereby inducing oligomerization. Furthermore, Gal-1 can trans-bridge α-DG core M1 structures and laminins, which proposed a possible mechanism by which Gal-1 ameliorates muscular dystrophies; however, this proposal warrants further investigation.
Collapse
|
7
|
Flanagan SP, Fogel R, Edkins AL, Ho LSJ, Limson J. Nonspecific nuclear uptake of anti-MUC1 aptamers by dead cells: the role of cell viability monitoring in aptamer targeting of membrane-bound protein cancer biomarkers. ANALYTICAL METHODS : ADVANCING METHODS AND APPLICATIONS 2021; 13:1191-1203. [PMID: 33605950 DOI: 10.1039/d0ay01878c] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
Most aptamers targeting cell-expressed antigens are intended for in vivo application, however, these sequences are commonly generated in vitro against synthetic oligopeptide epitopes or recombinant proteins. As these in vitro analogues frequently do not mimic the in vivo target within an endogenous environment, the evolved aptamers are often prone to nonspecific binding. The presence of dead cells and cellular debris further complicate aptamer targeting, due to their high nonspecific affinities to single-stranded DNA. Despite these known limitations, assessment of cell viability and/or the removal of dead cells is rarely applied as part of the methodology during in vivo testing of aptamer binding. Furthermore, the extent and route(s) by which dead cells uptake existing aptamers remains to be determined in the literature. For this purpose, the previously reported aptamer sequences 5TR1, 5TR4, 5TRG2 and S22 - enriched against the MUC1 tumour marker of the mucin glycoprotein family - were used as model sequences to evaluate the influence of cell viability and the presence of nontarget cell-expressed protein on aptamer binding to the MUC1 expressing human cancer cell lines MCF-7, Hs578T, SW480, and SW620. From fluorescence microscopy analysis, all tested aptamers demonstrated extensive nonspecific uptake within the nuclei of dead cells with compromised membrane integrities. Using fluorescent-activated cell sorting (FACS), the inclusion of excess double-stranded DNA as a blocking agent showed no effect on nonspecific aptamer uptake by dead cells. Further nonspecific binding to cell-membrane bound and intracellular protein was evident for each aptamer sequence, as assessed by southwestern blotting and FACS. These factors likely contributed to the ∼120-fold greater binding response of the 5TR1 aptamer to dead MCF-7 cells over equivalent live cell populations. The identification of dead cells and cellular debris using viability stains and the subsequent exclusion of these cells from FACS analysis was identified as an essential requirement for the evaluation of aptamer binding specificity to live cell populations of the cancer cell lines MCF-7, Hs578T and SW480. The research findings stress the importance of dead cell uptake and more comprehensive cell viability screening to validate novel aptamer sequences for diagnostic and therapeutic application.
Collapse
|
8
|
Sjögren J, Lood R, Nägeli A. On enzymatic remodeling of IgG glycosylation; unique tools with broad applications. Glycobiology 2020; 30:254-267. [PMID: 31616919 PMCID: PMC7109354 DOI: 10.1093/glycob/cwz085] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2019] [Revised: 09/05/2019] [Accepted: 09/30/2019] [Indexed: 01/14/2023] Open
Abstract
The importance of IgG glycosylation has been known for many years not only by scientists in glycobiology but also by human pathogens that have evolved specific enzymes to modify these glycans with fundamental impact on IgG function. The rise of IgG as a major therapeutic scaffold for many cancer and immunological indications combined with the availability of unique enzymes acting specifically on IgG Fc-glycans have spurred a range of applications to study this important post-translational modification on IgG. This review article introduces why the IgG glycans are of distinguished interest, gives a background on the unique enzymatic tools available to study the IgG glycans and finally presents an overview of applications utilizing these enzymes for various modifications of the IgG glycans. The applications covered include site-specific glycan transglycosylation and conjugation, analytical workflows for monoclonal antibodies and serum diagnostics. Additionally, the review looks ahead and discusses the importance of O-glycosylation for IgG3, Fc-fusion proteins and other new formats of biopharmaceuticals.
Collapse
Affiliation(s)
| | - Rolf Lood
- Genovis AB, Scheelevägen 2, 223 63 Lund, Sweden
| | | |
Collapse
|
9
|
Bose M, Mukherjee P. Potential of Anti-MUC1 Antibodies as a Targeted Therapy for Gastrointestinal Cancers. Vaccines (Basel) 2020; 8:E659. [PMID: 33167508 PMCID: PMC7712407 DOI: 10.3390/vaccines8040659] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2020] [Revised: 10/27/2020] [Accepted: 11/03/2020] [Indexed: 02/06/2023] Open
Abstract
Gastrointestinal cancers (GI) account for 26% of cancer incidences globally and 35% of all cancer-related deaths. The main challenge is to target cancer specific antigens. Mucins are heavily O-glycosylated proteins overexpressed in different cancers. The transmembrane glycoprotein MUC1 is the most likeable target for antibodies, owing to its specific overexpression and aberrant glycosylation in many types of cancers. For the past 30 years, MUC1 has remained a possible diagnostic marker and therapeutic target. Despite initiation of numerous clinical trials, a comprehensively effective therapy with clinical benefit is yet to be achieved. However, the interest in MUC1 as a therapeutic target remains unaltered. For all translational studies, it is important to incorporate updated relevant research findings into therapeutic strategies. In this review we present an overview of the antibodies targeting MUC1 in GI cancers, their potential role in immunotherapy (i.e., antibody-drug and radioimmunoconjugates, CAR-T cells), and other novel therapeutic strategies. We also present our perspectives on how the mechanisms of action of different anti-MUC1 antibodies can target specific hallmarks of cancer and therefore be utilized as a combination therapy for better clinical outcomes.
Collapse
Affiliation(s)
- Mukulika Bose
- Department of Biological Sciences, University of North Carolina, Charlotte, NC 28223, USA;
| | | |
Collapse
|
10
|
Guillen-Poza PA, Sánchez-Fernández EM, Artigas G, García Fernández JM, Hinou H, Ortiz Mellet C, Nishimura SI, Garcia-Martin F. Amplified Detection of Breast Cancer Autoantibodies Using MUC1-Based Tn Antigen Mimics. J Med Chem 2020; 63:8524-8533. [PMID: 32672464 DOI: 10.1021/acs.jmedchem.0c00908] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
In many human carcinomas, mucin-1 (MUC1) is overexpressed and aberrantly glycosylated, resulting in the exposure of previously hidden antigens. This generates new patient antibody profiles that can be used in cancer diagnosis. In the present study, we focused on the MUC1-associated Tn antigen (α-O-GalNAc-Ser/Thr) and substituted the GalNAc monosaccharide by a glycomimic to identify MUC1-based glycopeptides with increased antigenicity. Two different glycopeptide libraries presenting the natural Tn antigen or the sp2-iminosugar analogue were synthesized and evaluated with anti-MUC1 monoclonal antibodies in a microarray platform. The most promising candidates were tested with healthy and breast cancer sera aiming for potential autoantibody-based biomarkers. The suitability of sp2-iminosugar glycopeptides to detect anti-MUC1 antibodies was demonstrated, and serological experiments showed stage I breast cancer autoantibodies binding with a specific unnatural glycopeptide with almost no healthy serum interaction. These results will promote further studies on their capabilities as early cancer biomarkers.
Collapse
Affiliation(s)
- Pablo A Guillen-Poza
- Field of Drug Discovery Research, Faculty of Advanced Life Science, and Graduate School of Life Science, Hokkaido University, N21 W11, Kita-ku, 001-0021 Sapporo, Japan
| | - Elena M Sánchez-Fernández
- Department of Organic Chemistry, Faculty of Chemistry, University of Seville, E-41012 Seville, Spain
| | - Gerard Artigas
- Field of Drug Discovery Research, Faculty of Advanced Life Science, and Graduate School of Life Science, Hokkaido University, N21 W11, Kita-ku, 001-0021 Sapporo, Japan
| | | | - Hiroshi Hinou
- Field of Drug Discovery Research, Faculty of Advanced Life Science, and Graduate School of Life Science, Hokkaido University, N21 W11, Kita-ku, 001-0021 Sapporo, Japan
| | - Carmen Ortiz Mellet
- Department of Organic Chemistry, Faculty of Chemistry, University of Seville, E-41012 Seville, Spain
| | - Shin-Ichiro Nishimura
- Field of Drug Discovery Research, Faculty of Advanced Life Science, and Graduate School of Life Science, Hokkaido University, N21 W11, Kita-ku, 001-0021 Sapporo, Japan
| | - Fayna Garcia-Martin
- Field of Drug Discovery Research, Faculty of Advanced Life Science, and Graduate School of Life Science, Hokkaido University, N21 W11, Kita-ku, 001-0021 Sapporo, Japan
| |
Collapse
|
11
|
Wakui H, Tanaka Y, Ose T, Matsumoto I, Kato K, Min Y, Tachibana T, Sato M, Naruchi K, Martin FG, Hinou H, Nishimura SI. A straightforward approach to antibodies recognising cancer specific glycopeptidic neoepitopes. Chem Sci 2020; 11:4999-5006. [PMID: 34122956 PMCID: PMC8159228 DOI: 10.1039/d0sc00317d] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2020] [Revised: 11/18/2020] [Accepted: 04/23/2020] [Indexed: 12/14/2022] Open
Abstract
Aberrantly truncated immature O-glycosylation in proteins occurs in essentially all types of epithelial cancer cells, which was demonstrated to be a common feature of most adenocarcinomas and strongly associated with cancer proliferation and metastasis. Although extensive efforts have been made toward the development of anticancer antibodies targeting MUC1, one of the most studied mucins having cancer-relevant immature O-glycans, no anti-MUC1 antibody recognises carbohydrates and the proximal MUC1 peptide region, concurrently. Here we present a general strategy that allows for the creation of antibodies interacting specifically with glycopeptidic neoepitopes by using homogeneous synthetic MUC1 glycopeptides designed for the streamlined process of immunization, antibody screening, three-dimensional structure analysis, epitope mapping and biochemical analysis. The X-ray crystal structure of the anti-MUC1 monoclonal antibody SN-101 complexed with the antigenic glycopeptide provides for the first time evidence that SN-101 recognises specifically the essential epitope by forming multiple hydrogen bonds both with the proximal peptide and GalNAc linked to the threonine residue, concurrently. Remarkably, the structure of the MUC1 glycopeptide in complex with SN-101 is identical to its solution NMR structure, an extended conformation induced by site-specific glycosylation. We demonstrate that this method accelerates dramatically the development of a new class of designated antibodies targeting a variety of "dynamic neoepitopes" elaborated by disease-specific O-glycosylation in the immunodominant mucin domains and mucin-like sequences found in intrinsically disordered regions of many proteins.
Collapse
Affiliation(s)
- Hajime Wakui
- Field of Drug Discovery Research, Faculty of Advanced Life Science, Graduate School of Life Science, Hokkaido University N21 W11, Kita-ku Sapporo 001-0021 Japan
| | - Yoshikazu Tanaka
- Graduate School of Life Sciences, Tohoku University 2-1-1 Katahira, Aoba-ku Sendai 980-8577 Japan
| | - Toyoyuki Ose
- Field of X-ray Structural Biology, Faculty of Advanced Life Science, Graduate School of Life Science, Hokkaido University N10 W8, Kita-ku Sapporo 060-0810 Japan
| | - Isamu Matsumoto
- Field of X-ray Structural Biology, Faculty of Advanced Life Science, Graduate School of Life Science, Hokkaido University N10 W8, Kita-ku Sapporo 060-0810 Japan
| | - Koji Kato
- Research Institute for Interdisciplinary Science and Graduate School of Natural Science and Technology, Okayama University 3-1-1, Tsushima-naka, Kita-ku Okayama 700-8530 Japan
| | - Yao Min
- Field of X-ray Structural Biology, Faculty of Advanced Life Science, Graduate School of Life Science, Hokkaido University N10 W8, Kita-ku Sapporo 060-0810 Japan
| | - Taro Tachibana
- Department of Bioengineering, Graduate School of Engineering, Osaka City University Sumiyoshi-ku Osaka 558-8585 Japan
| | - Masaharu Sato
- Medicinal Chemistry Pharmaceuticals, Co., Ltd. N9 W15, Chuo-ku Sapporo 060-0009 Japan
| | - Kentaro Naruchi
- Medicinal Chemistry Pharmaceuticals, Co., Ltd. N9 W15, Chuo-ku Sapporo 060-0009 Japan
| | - Fayna Garcia Martin
- Field of Drug Discovery Research, Faculty of Advanced Life Science, Graduate School of Life Science, Hokkaido University N21 W11, Kita-ku Sapporo 001-0021 Japan
| | - Hiroshi Hinou
- Field of Drug Discovery Research, Faculty of Advanced Life Science, Graduate School of Life Science, Hokkaido University N21 W11, Kita-ku Sapporo 001-0021 Japan
| | - Shin-Ichiro Nishimura
- Field of Drug Discovery Research, Faculty of Advanced Life Science, Graduate School of Life Science, Hokkaido University N21 W11, Kita-ku Sapporo 001-0021 Japan
| |
Collapse
|
12
|
Impaired O-Glycosylation at Consecutive Threonine TTX Motifs in Mucins Generates Conformationally Restricted Cancer Neoepitopes. Biochemistry 2020; 59:1221-1241. [PMID: 32155332 DOI: 10.1021/acs.biochem.0c00007] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Autoantibody signatures of circulating mucin fragments stem from cancer tissues, and microenvironments are promising biomarkers for cancer diagnosis and therapy. This study highlights dynamic epitopes generated by aberrantly truncated immature O-glycosylation at consecutive threonine motifs (TTX) found in mucins and intrinsically disordered proteins (IDPs). NMR analysis of synthetic mucin models having glycosylated TTX motifs and colonic MUC2 tandem repeats (TRs) containing TTP and TTL moieties unveils a general principle that O-glycosylation at TTX motifs generates a highly extended and rigid conformation in IDPs. We demonstrate that the specific conformation of glycosylated TTX motifs in MUC2 TRs is rationally rearranged by concerted motions of multiple dihedral angles and noncovalent interactions between the carbohydrate and peptide region. Importantly, this canonical conformation of glycosylated TTX motifs minimizes steric crowding of glycans attached to threonine residues, in which O-glycans possess restricted orientations permitting further sugar extension. An antiadhesive microarray displaying synthetic MUC2 derivatives elicited the presence of natural autoantibodies to MUC2 with impaired O-glycosylation at TTX motifs in sera of healthy volunteers and patients diagnosed with early stage colorectal cancer (CRC). Interestingly, autoantibody levels in sera of the late stage CRC patients were distinctly lower than those of early stage CRC and normal individuals, indicating that the anti-MUC2 humoral response to MUC2 neoepitopes correlates inversely with the CRC stage of patients. Our results uncovered the structural basis of the creation of dynamic epitopes by immature O-glycosylation at TTX motifs in mucins that facilitates the identification of high-potential targets for cancer diagnosis and therapy.
Collapse
|
13
|
Beckwith DM, Cudic M. Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design. Semin Immunol 2020; 47:101389. [PMID: 31926647 DOI: 10.1016/j.smim.2020.101389] [Citation(s) in RCA: 53] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/29/2019] [Accepted: 01/01/2020] [Indexed: 02/07/2023]
Abstract
The transformation from normal to malignant phenotype in human cancers is associated with aberrant cell-surface glycosylation. It has frequently been reported that MUC1, the heavily glycosylated cell-surface mucin, is altered in both, expression and glycosylation pattern, in human carcinomas of the epithelium. The presence of incomplete or truncated glycan structures, often capped by sialic acid, commonly known as tumor-associated carbohydrate antigens (TACAs), play a key role in tumor initiation, progression, and metastasis. Accumulating evidence suggests that expression of TACAs is associated with tumor escape from immune defenses. In this report, we will give an overview of the oncogenic functions of MUC1 that are exerted through TACA interactions with endogenous carbohydrate-binding proteins (lectins). These interactions often lead to creation of a pro-tumor microenvironment, favoring tumor progression and metastasis, and tumor evasion. In addition, we will describe current efforts in the design of cancer vaccines with special emphasis on synthetic MUC1 glycopeptide vaccines. Analysis of the key factors that govern structure-based design of immunogenic MUC1 glycopeptide epitopes are described. The role of TACA type, position, and density on observed humoral and cellular immune responses is evaluated.
Collapse
Affiliation(s)
- Donella M Beckwith
- Department of Chemistry and Biochemistry, Charles E. Schmidt College of Science, Florida Atlantic University, 777 Glades Road, Boca Raton, Florida 33431, United States
| | - Maré Cudic
- Department of Chemistry and Biochemistry, Charles E. Schmidt College of Science, Florida Atlantic University, 777 Glades Road, Boca Raton, Florida 33431, United States.
| |
Collapse
|
14
|
Singh Y, Rodriguez Benavente MC, Al-Huniti MH, Beckwith D, Ayyalasomayajula R, Patino E, Miranda WS, Wade A, Cudic M. Positional Scanning MUC1 Glycopeptide Library Reveals the Importance of PDTR Epitope Glycosylation for Lectin Binding. J Org Chem 2019; 85:1434-1445. [PMID: 31799848 PMCID: PMC7012140 DOI: 10.1021/acs.joc.9b02396] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
One of the main barriers to explaining the functional significance of glycan-based changes in cancer is the natural epitope heterogeneity found on the surface of cancer cells. To help address this knowledge gap, we focused on designing synthetic tools to explore the role of tumor-associated glycans of MUC1 in the formation of metastasis via association with lectins. In this study, we have synthesized for the first time a MUC1-derived positional scanning synthetic glycopeptide combinatorial library (PS-SGCL) that vary in number and location of cancer-associated Tn antigen using the "tea bag" approach. The determination of the isokinetic ratios necessary for the equimolar incorporation of (glyco)amino acids mixtures to resin-bound amino acid was determined, along with developing an efficient protocol for on resin deprotection of O-acetyl groups. Enzyme-linked lectin assay was used to screen PS-SGCL against two plant lectins, Glycine max soybean agglutinin and Vicia villosa. The results revealed a carbohydrate density-dependent affinity trend and site-specific glycosylation requirements for high affinity binding to these lectins. Hence, PS-SGCLs provide a platform to systematically elucidate MUC1-lectin binding specificities, which in the long term may provide a rational design for novel inhibitors of MUC1-lectin interactions involved in tumor spread and glycopeptide-based cancer vaccines.
Collapse
Affiliation(s)
- YashoNandini Singh
- From the Department of Chemistry and Biochemistry, Charles E. Schmidt College of Science , Florida Atlantic University , 777 Glades Road , Boca Raton , Florida 33431 , United States
| | - Maria C Rodriguez Benavente
- From the Department of Chemistry and Biochemistry, Charles E. Schmidt College of Science , Florida Atlantic University , 777 Glades Road , Boca Raton , Florida 33431 , United States
| | - Mohammed H Al-Huniti
- From the Department of Chemistry and Biochemistry, Charles E. Schmidt College of Science , Florida Atlantic University , 777 Glades Road , Boca Raton , Florida 33431 , United States
| | - Donella Beckwith
- From the Department of Chemistry and Biochemistry, Charles E. Schmidt College of Science , Florida Atlantic University , 777 Glades Road , Boca Raton , Florida 33431 , United States
| | - Ramya Ayyalasomayajula
- From the Department of Chemistry and Biochemistry, Charles E. Schmidt College of Science , Florida Atlantic University , 777 Glades Road , Boca Raton , Florida 33431 , United States
| | - Eric Patino
- From the Department of Chemistry and Biochemistry, Charles E. Schmidt College of Science , Florida Atlantic University , 777 Glades Road , Boca Raton , Florida 33431 , United States
| | - William S Miranda
- From the Department of Chemistry and Biochemistry, Charles E. Schmidt College of Science , Florida Atlantic University , 777 Glades Road , Boca Raton , Florida 33431 , United States
| | - Alex Wade
- From the Department of Chemistry and Biochemistry, Charles E. Schmidt College of Science , Florida Atlantic University , 777 Glades Road , Boca Raton , Florida 33431 , United States
| | - Maré Cudic
- From the Department of Chemistry and Biochemistry, Charles E. Schmidt College of Science , Florida Atlantic University , 777 Glades Road , Boca Raton , Florida 33431 , United States
| |
Collapse
|
15
|
Tommasone S, Allabush F, Tagger YK, Norman J, Köpf M, Tucker JHR, Mendes PM. The challenges of glycan recognition with natural and artificial receptors. Chem Soc Rev 2019; 48:5488-5505. [PMID: 31552920 DOI: 10.1039/c8cs00768c] [Citation(s) in RCA: 91] [Impact Index Per Article: 18.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Glycans - simple or complex carbohydrates - play key roles as recognition determinants and modulators of numerous physiological and pathological processes. Thus, many biotechnological, diagnostic and therapeutic opportunities abound for molecular recognition entities that can bind glycans with high selectivity and affinity. This review begins with an overview of the current biologically and synthetically derived glycan-binding scaffolds that include antibodies, lectins, aptamers and boronic acid-based entities. It is followed by a more detailed discussion on various aspects of their generation, structure and recognition properties. It serves as the basis for highlighting recent key developments and technical challenges that must be overcome in order to fully deal with the specific recognition of a highly diverse and complex range of glycan structures.
Collapse
Affiliation(s)
- Stefano Tommasone
- School of Chemical Engineering, University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.
| | | | | | | | | | | | | |
Collapse
|
16
|
Products of Chemoenzymatic Synthesis Representing MUC1 Tandem Repeat Unit with T-, ST- or STn-antigen Revealed Distinct Specificities of Anti-MUC1 Antibodies. Sci Rep 2019; 9:16641. [PMID: 31719620 PMCID: PMC6851390 DOI: 10.1038/s41598-019-53052-1] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2019] [Accepted: 10/25/2019] [Indexed: 12/15/2022] Open
Abstract
Anti-mucin1 (MUC1) antibodies have long been used clinically in cancer diagnosis and therapy and specific bindings of some of them are known to be dependent on the differential glycosylation of MUC1. However, a systematic comparison of the binding specificities of anti-MUC1 antibodies was not previously conducted. Here, a total of 20 glycopeptides including the tandem repeat unit of MUC1, APPAHGVTSAPDTRPAPGSTAPPAHGV with GalNAc (Tn-antigen), Galβ1-3GalNAc (T-antigen), NeuAcα2-3Galβ1-3GalNAc (sialyl-T-antigen), or NeuAcα2-6GalNAc (sialyl-Tn-antigen) at each threonine or serine residue were prepared by a combination of chemical glycopeptide synthesis and enzymatic extension of carbohydrate chains. These glycopeptides were tested by the enzyme-linked immunosorbent assay (ELISA) for their capacity to bind 13 monoclonal antibodies (mAbs) known to be specific for MUC1. The results indicated that anti-MUC1 mAbs have diverse specificities but can be classified into a few characteristic groups based on their binding pattern toward glycopeptides in some cases having a specific glycan at unique glycosylation sites. Because the clinical significance of some of these antibodies was already established, the structural features identified by these antibodies as revealed in the present study should provide useful information relevant to their further clinical use and the biological understanding of MUC1.
Collapse
|
17
|
Hinou H, Kikuchi S, Ochi R, Igarashi K, Takada W, Nishimura SI. Synthetic glycopeptides reveal specific binding pattern and conformational change at O-mannosylated position of α-dystroglycan by POMGnT1 catalyzed GlcNAc modification. Bioorg Med Chem 2019; 27:2822-2831. [PMID: 31079966 DOI: 10.1016/j.bmc.2019.05.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2019] [Revised: 05/03/2019] [Accepted: 05/05/2019] [Indexed: 01/06/2023]
Abstract
Structural and functional effects of core M1 type glycan modification catalyzed by protein O-linked mannose β1,2-N-acetylglucosaminyltransferase 1 (POMGnT1) were investigated using a core M1 glycoform focused library of an α-dystroglycan fragment, 372TRGAIIQTPTLGPIQPTRV390. Evanescent-field fluorescence-assisted microarray system illuminated the specific binding pattern of plant lectins that can discriminate the glycan structure of core M1 glycan of the library. The comparative NMR analysis of synthetic glycopeptide having different length of the O-mannosylated glycans revealed a conformational change of the peptide backbone along with core M1 disaccharide formation. No long-range NOE signals of glycan-amino acid nor inter amino acid indicate the conformational change is induced by steric hindrance of core M1, the sole 1,2-O-modified form among protein binding sugar residue found in mammals.
Collapse
Affiliation(s)
- Hiroshi Hinou
- Graduate School of Life Science, Frontier Research Center for Advanced Material & Life Science, Hokkaido University, N21, W11, Sapporo 001-0021, Japan; Medicinal Chemistry Pharmaceuticals Co. Ltd., Sapporo, Japan.
| | - Seiya Kikuchi
- Graduate School of Life Science, Frontier Research Center for Advanced Material & Life Science, Hokkaido University, N21, W11, Sapporo 001-0021, Japan
| | - Rika Ochi
- Graduate School of Life Science, Frontier Research Center for Advanced Material & Life Science, Hokkaido University, N21, W11, Sapporo 001-0021, Japan
| | | | | | - Shin-Ichiro Nishimura
- Graduate School of Life Science, Frontier Research Center for Advanced Material & Life Science, Hokkaido University, N21, W11, Sapporo 001-0021, Japan; Medicinal Chemistry Pharmaceuticals Co. Ltd., Sapporo, Japan
| |
Collapse
|
18
|
Bello C, Rovero P, Papini AM. Just a spoonful of sugar: Short glycans affect protein properties and functions. J Pept Sci 2019; 25:e3167. [PMID: 30924227 DOI: 10.1002/psc.3167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2018] [Revised: 02/21/2019] [Accepted: 02/22/2019] [Indexed: 11/09/2022]
Abstract
Glycosylation has a strong impact on the chemical and physical properties of proteins and on their activity. The heterogeneous nature of this modification complicates the elucidation of the role of each glycan, thus slowing down the progress in glycobiology. Nevertheless, the great advances recently made in protein engineering and in the chemical synthesis, and semisynthesis of glycoproteins are giving impulse to the field, fostering important discoveries. In this review, we report on the findings of the last two decades on the importance that the attachment site, linkage, and composition of short glycans have in affecting protein properties and functions.
Collapse
Affiliation(s)
- Claudia Bello
- Laboratory of Peptide and Protein Chemistry and Biology, Department of Chemistry "Ugo Schiff", University of Florence, Sesto Fiorentino, Italy
| | - Paolo Rovero
- Laboratory of Peptide and Protein Chemistry and Biology, Department of NeuroFarBa, University of Florence, Sesto Fiorentino, Italy
| | - Anna Maria Papini
- Laboratory of Peptide and Protein Chemistry and Biology, Department of Chemistry "Ugo Schiff", University of Florence, Sesto Fiorentino, Italy.,PeptLab@UCP Platform and Laboratory of Chemical Biology EA4505, University Paris-Seine, Cergy-Pontoise CEDEX, France
| |
Collapse
|
19
|
Trabbic KR, Kleski KA, Shi M, Bourgault JP, Prendergast JM, Dransfield DT, Andreana PR. Production of a mouse monoclonal IgM antibody that targets the carbohydrate Thomsen-nouveau cancer antigen resulting in in vivo and in vitro tumor killing. Cancer Immunol Immunother 2018; 67:1437-1447. [PMID: 30030557 PMCID: PMC11028060 DOI: 10.1007/s00262-018-2206-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2017] [Accepted: 07/09/2018] [Indexed: 11/29/2022]
Abstract
The construction of a tumor-associated carbohydrate antigen-zwitterionic polysaccharide conjugate, Thomsen-nouveau-polysaccharide A1 (Tn-PS A1, where Tn = D-GalpNAc), has led to the development of a carbohydrate binding monoclonal antibody named Kt-IgM-8. Kt-IgM-8 was produced via hybridoma from Tn-PS A1 hyperimmunized Jackson Laboratory C57BL/6 mice, splenocytes and the murine myeloma cell line Sp2/0Ag14 with subsequent cloning on methyl cellulose semi-solid media. This in-house generated monoclonal antibody negates binding influenced from peptides, proteins, and lipids and preferentially binds monovalent Tn antigen as noted by ELISA, FACS, and glycan array technologies. Kt-IgM-8 demonstrated in vitro and in vivo tumor killing against the Michigan Cancer Foundation breast cell line 7 (MCF-7). In vitro tumor killing was observed using an LDH assay that measured antibody-induced complement-dependent cytotoxicity and these results were validated in an in vivo passive immunotherapy approach using an MCF-7 cell line-derived xenograft model. Kt-IgM-8 is effective in killing tumor cells at 30% cytotoxicity, and furthermore, it demonstrated approximately 40% reduction in tumor growth in the MCF-7 model.
Collapse
Affiliation(s)
- Kevin R Trabbic
- Department of Chemistry and Biochemistry, School of Green Chemistry and Engineering, The University of Toledo, 2801 West Bancroft Street, Wolfe Hall 2232B, Toledo, OH, 43606, USA
| | - Kristopher A Kleski
- Department of Chemistry and Biochemistry, School of Green Chemistry and Engineering, The University of Toledo, 2801 West Bancroft Street, Wolfe Hall 2232B, Toledo, OH, 43606, USA
| | - Mengchao Shi
- Department of Chemistry and Biochemistry, School of Green Chemistry and Engineering, The University of Toledo, 2801 West Bancroft Street, Wolfe Hall 2232B, Toledo, OH, 43606, USA
| | - Jean-Paul Bourgault
- Department of Chemistry and Biochemistry, School of Green Chemistry and Engineering, The University of Toledo, 2801 West Bancroft Street, Wolfe Hall 2232B, Toledo, OH, 43606, USA
| | | | | | - Peter R Andreana
- Department of Chemistry and Biochemistry, School of Green Chemistry and Engineering, The University of Toledo, 2801 West Bancroft Street, Wolfe Hall 2232B, Toledo, OH, 43606, USA.
| |
Collapse
|
20
|
Pinger J, Nešić D, Ali L, Aresta-Branco F, Lilic M, Chowdhury S, Kim HS, Verdi J, Raper J, Ferguson MAJ, Papavasiliou FN, Stebbins CE. African trypanosomes evade immune clearance by O-glycosylation of the VSG surface coat. Nat Microbiol 2018; 3:932-938. [PMID: 29988048 PMCID: PMC6108419 DOI: 10.1038/s41564-018-0187-6] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2018] [Accepted: 06/04/2018] [Indexed: 11/09/2022]
Abstract
The African trypanosome Trypanosoma brucei spp. is a paradigm for antigenic variation, the orchestrated alteration of cell surface molecules to evade host immunity. The parasite elicits robust antibody-mediated immune responses to its variant surface glycoprotein (VSG) coat, but evades immune clearance by repeatedly accessing a large genetic VSG repertoire and 'switching' to antigenically distinct VSGs. This persistent immune evasion has been ascribed exclusively to amino-acid variance on the VSG surface presented by a conserved underlying protein architecture. We establish here that this model does not account for the scope of VSG structural and biochemical diversity. The 1.4-Å-resolution crystal structure of the variant VSG3 manifests divergence in the tertiary fold and oligomeric state. The structure also reveals an O-linked carbohydrate on the top surface of VSG3. Mass spectrometric analysis indicates that this O-glycosylation site is heterogeneously occupied in VSG3 by zero to three hexose residues and is also present in other VSGs. We demonstrate that this O-glycosylation increases parasite virulence by impairing the generation of protective immunity. These data alter the paradigm of antigenic variation by the African trypanosome, expanding VSG variability beyond amino-acid sequence to include surface post-translational modifications with immunomodulatory impact.
Collapse
Affiliation(s)
- Jason Pinger
- The Rockefeller University, Laboratory of Lymphocyte Biology, New York, NY, USA
| | - Dragana Nešić
- The Rockefeller University, Laboratory of Structural Microbiology, New York, NY, USA.,The Rockefeller University, Allen and Frances Adler Laboratory of Blood and Vascular Biology, New York, NY, USA
| | - Liaqat Ali
- Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dundee, UK
| | - Francisco Aresta-Branco
- Division of Immune Diversity, German Cancer Research Center, Heidelberg, Germany.,Division of Structural Biology of Infection and Immunity, German Cancer Research Center, Heidelberg, Germany
| | - Mirjana Lilic
- The Rockefeller University, Laboratory of Structural Microbiology, New York, NY, USA.,The Rockefeller University, Laboratory of Molecular Biophysics, New York, NY, USA
| | - Shanin Chowdhury
- The Rockefeller University, Laboratory of Lymphocyte Biology, New York, NY, USA
| | - Hee-Sook Kim
- The Rockefeller University, Laboratory of Lymphocyte Biology, New York, NY, USA
| | - Joseph Verdi
- Department of Biological Sciences, Hunter College, City University of New York, New York, NY, USA
| | - Jayne Raper
- Department of Biological Sciences, Hunter College, City University of New York, New York, NY, USA
| | - Michael A J Ferguson
- Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, Dundee, UK.
| | - F Nina Papavasiliou
- Division of Immune Diversity, German Cancer Research Center, Heidelberg, Germany.
| | - C Erec Stebbins
- Division of Structural Biology of Infection and Immunity, German Cancer Research Center, Heidelberg, Germany.
| |
Collapse
|
21
|
Movahedin M, Brooks TM, Supekar NT, Gokanapudi N, Boons GJ, Brooks CL. Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen. Glycobiology 2018; 27:677-687. [PMID: 28025250 DOI: 10.1093/glycob/cww131] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2016] [Accepted: 12/14/2016] [Indexed: 12/30/2022] Open
Abstract
In cancer cells, the glycoprotein Mucin 1 (MUC1) undergoes abnormal, truncated glycosylation. The truncated glycosylation exposes cryptic peptide epitopes that can be recognized by antibodies. Since these immunogenic regions are cancer specific, they represent ideal targets for therapeutic antibodies. We investigated the role of tumor-specific glycosylation on antigen recognition by the therapeutic antibody AR20.5. We explored the affinity of AR20.5 to a synthetic cancer-specific MUC1 glycopeptide and peptide. The antibody bound to the glycopeptide with an order of magnitude stronger affinity than the naked peptide. Given these results, we postulated that AR20.5 must specifically bind the carbohydrate as well as the peptide. Using X-ray crystallography, we examined this hypothesis by determining the structure of AR20.5 in complex with both peptide and glycopeptide. Surprisingly, the structure revealed that the carbohydrate did not form any specific polar contacts with the antibody. The high affinity of AR20.5 for the glycopeptide and the lack of specific binding contacts support a hypothesis that glycosylation of MUC1 stabilizes an extended bioactive conformation of the peptide recognized by the antibody. Since high affinity binding of AR20.5 to the MUC1 glycopeptide may not driven by specific antibody-antigen contacts, but rather evidence suggests that glycosylation alters the conformational equilibrium of the antigen, which allows the antibody to select the correct conformation. This study suggests a novel mechanism of antibody-antigen interaction and also suggests that glycosylation of MUC1 is important for the generation of high affinity therapeutic antibodies.
Collapse
Affiliation(s)
- Mohammadreza Movahedin
- Department of Chemistry, California State University Fresno, 2555 E San Ramon Ave, Fresno, CA 93740, USA
| | - Teresa M Brooks
- Department of Chemistry, California State University Fresno, 2555 E San Ramon Ave, Fresno, CA 93740, USA
| | - Nitin T Supekar
- Complex Carbohydrate Research Center, 315 Riverbend Road, Athens, GA 30602, USA.,Department of Chemistry, University of Georgia, 140 Cedar street, Athens, GA 30602, USA
| | - Naveen Gokanapudi
- Department of Chemistry, California State University Fresno, 2555 E San Ramon Ave, Fresno, CA 93740, USA
| | - Geert-Jan Boons
- Complex Carbohydrate Research Center, 315 Riverbend Road, Athens, GA 30602, USA.,Department of Chemistry, University of Georgia, 140 Cedar street, Athens, GA 30602, USA.,Department of Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, and Bijvoet Center for Biomolecular Research, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands
| | - Cory L Brooks
- Department of Chemistry, California State University Fresno, 2555 E San Ramon Ave, Fresno, CA 93740, USA
| |
Collapse
|
22
|
Martínez-Sáez N, Peregrina JM, Corzana F. Principles of mucin structure: implications for the rational design of cancer vaccines derived from MUC1-glycopeptides. Chem Soc Rev 2018; 46:7154-7175. [PMID: 29022615 DOI: 10.1039/c6cs00858e] [Citation(s) in RCA: 67] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Cancer is currently one of the world's most serious public health problems. Significant efforts are being made to develop new strategies that can eradicate tumours selectively without detrimental effects to healthy cells. One promising approach is focused on the design of vaccines that contain partially glycosylated mucins in their formulation. Although some of these vaccines are in clinical trials, a lack of knowledge about the molecular basis that governs the antigen presentation, and the interactions between antigens and the elicited antibodies has limited their success thus far. This review focuses on the most significant milestones achieved to date in the conformational analysis of tumour-associated MUC1 derivatives both in solution and bound to antibodies. The effect that the carbohydrate scaffold has on the peptide backbone structure and the role of the sugar in molecular recognition by antibodies are emphasised. The outcomes summarised in this review may be a useful guide to develop new antigens for the design of cancer vaccines in the near future.
Collapse
Affiliation(s)
- Nuria Martínez-Sáez
- Departamento de Química, Universidad de La Rioja, Centro de Investigación en Síntesis Química, 26006 Logroño, Spain.
| | | | | |
Collapse
|
23
|
Supekar NT, Lakshminarayanan V, Capicciotti CJ, Sirohiwal A, Madsen CS, Wolfert MA, Cohen PA, Gendler SJ, Boons GJ. Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide. Chembiochem 2018; 19:121-125. [PMID: 29120508 PMCID: PMC5975269 DOI: 10.1002/cbic.201700424] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2017] [Indexed: 12/16/2022]
Abstract
A fully synthetic MUC1-based cancer vaccine was designed and chemically synthesized containing an endogenous helper T-epitope (MHC class II epitope). The vaccine elicited robust IgG titers that could neutralize cancer cells by antibody-dependent cell-mediated cytotoxicity (ADCC). It also activated cytotoxic T-lymphocytes. Collectively, the immunological data demonstrate engagement of helper T-cells in immune activation. A synthetic methodology was developed for a penta-glycosylated MUC1 glycopeptide, and antisera of mice immunized by the new vaccine recognized such a structure. Previously reported fully synthetic MUC1-based cancer vaccines that elicited potent immune responses employed exogenous helper T-epitopes derived from microbes. It is the expectation that the use of the newly identified endogenous helper T-epitope will be more attractive, because it will activate cognate CD4+ T-cells that will provide critical tumor-specific help intratumorally during the effector stage of tumor rejection and will aid in the generation of sustained immunological memory.
Collapse
Affiliation(s)
- Nitin T Supekar
- Complex Carbohydrate Research Center, The University of Georgia, 315 Riverbend Road, Athens, Georgia, 30602, USA
- Department of Chemistry, The University of Georgia, 140 Cedar Street, Athens, Georgia, 30602, USA
| | - Vani Lakshminarayanan
- Departments of Biochemistry and Molecular Biology and Immunology, Mayo Clinic College of Medicine and, Mayo Clinic Comprehensive Cancer Center, 13400 East Shea Boulevard, Scottsdale, AZ, 85259, USA
| | - Chantelle J Capicciotti
- Complex Carbohydrate Research Center, The University of Georgia, 315 Riverbend Road, Athens, Georgia, 30602, USA
| | - Anju Sirohiwal
- Complex Carbohydrate Research Center, The University of Georgia, 315 Riverbend Road, Athens, Georgia, 30602, USA
| | - Cathy S Madsen
- Departments of Biochemistry and Molecular Biology and Immunology, Mayo Clinic College of Medicine and, Mayo Clinic Comprehensive Cancer Center, 13400 East Shea Boulevard, Scottsdale, AZ, 85259, USA
| | - Margreet A Wolfert
- Complex Carbohydrate Research Center, The University of Georgia, 315 Riverbend Road, Athens, Georgia, 30602, USA
- Department of Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences and, Bijvoet Center for Biomolecular Research, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, Netherlands
| | - Peter A Cohen
- Departments of Biochemistry and Molecular Biology and Immunology, Mayo Clinic College of Medicine and, Mayo Clinic Comprehensive Cancer Center, 13400 East Shea Boulevard, Scottsdale, AZ, 85259, USA
| | - Sandra J Gendler
- Departments of Biochemistry and Molecular Biology and Immunology, Mayo Clinic College of Medicine and, Mayo Clinic Comprehensive Cancer Center, 13400 East Shea Boulevard, Scottsdale, AZ, 85259, USA
| | - Geert-Jan Boons
- Complex Carbohydrate Research Center, The University of Georgia, 315 Riverbend Road, Athens, Georgia, 30602, USA
- Department of Chemistry, The University of Georgia, 140 Cedar Street, Athens, Georgia, 30602, USA
- Department of Chemical Biology and Drug Discovery, Utrecht Institute for Pharmaceutical Sciences and, Bijvoet Center for Biomolecular Research, Utrecht University, Universiteitsweg 99, 3584 CG, Utrecht, Netherlands
| |
Collapse
|
24
|
Naito S, Takahashi T, Onoda J, Uemura S, Ohyabu N, Takemoto H, Yamane S, Fujii I, Nishimura SI, Numata Y. Generation of Novel Anti-MUC1 Monoclonal Antibodies with Designed Carbohydrate Specificities Using MUC1 Glycopeptide Library. ACS OMEGA 2017; 2:7493-7505. [PMID: 30023556 PMCID: PMC6044872 DOI: 10.1021/acsomega.7b00708] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 05/31/2017] [Accepted: 10/09/2017] [Indexed: 06/08/2023]
Abstract
Numerous anti-mucin 1 (anti-MUC1) antibodies that recognize O-glycan core structures have already been developed. However, most of them show low specificities toward O-glycan structures and/or low affinity toward a monovalent epitope. In this study, using an MUC1 glycopeptide library, we established two novel anti-MUC1 monoclonal antibodies (1B2 and 12D10) with designed carbohydrate specificities. Compared with previously reported anti-MUC1 antibodies, 1B2 and 12D10 showed quite different features regarding their specificities, affinities, and reactivity profiles to various cell lines. Both antibodies recognized specific O-glycan structures at the PDT*R motif (the asterisk represents an O-glycosylation site). 1B2 recognized O-glycans with an unsubstituted O-6 position of the GalNAc residue (Tn, T, and 23ST), whereas 12D10 recognized Neu5Ac at the same position (STn, 26ST, and dST). Neither of them bound to glycopeptides with core 2 O-glycans that have GlcNAc at the O-6 position of the GalNAc residue. Furthermore, 1B2 and 12D10 showed a strong binding to not only native MUC1 but also 20-mer glycopeptide with a monovalent epitope. These anti-MUC1 antibodies should thus become powerful tools for biological studies on MUC1 O-glycan structures. Furthermore, the strategy of using glycopeptide libraries should enable the development of novel antibodies with predesigned O-glycan specificities.
Collapse
Affiliation(s)
- Shoichi Naito
- Shionogi
Pharmaceutical Research Center, Shionogi
& Co., Ltd., 3-1-1
Futaba-cho, Toyonaka, Osaka 561-0825, Japan
| | - Tatsuya Takahashi
- Shionogi
Pharmaceutical Research Center, Shionogi
& Co., Ltd., 3-1-1
Futaba-cho, Toyonaka, Osaka 561-0825, Japan
| | - Junji Onoda
- Shionogi
Pharmaceutical Research Center, Shionogi
& Co., Ltd., 3-1-1
Futaba-cho, Toyonaka, Osaka 561-0825, Japan
| | - Shoko Uemura
- Shionogi
Pharmaceutical Research Center, Shionogi
& Co., Ltd., 3-1-1
Futaba-cho, Toyonaka, Osaka 561-0825, Japan
| | - Naoki Ohyabu
- Shionogi
Pharmaceutical Research Center, Shionogi
& Co., Ltd., 3-1-1
Futaba-cho, Toyonaka, Osaka 561-0825, Japan
| | - Hiroshi Takemoto
- Shionogi
Pharmaceutical Research Center, Shionogi
& Co., Ltd., 3-1-1
Futaba-cho, Toyonaka, Osaka 561-0825, Japan
| | - Shoji Yamane
- Shionogi
Pharmaceutical Research Center, Shionogi
& Co., Ltd., 3-1-1
Futaba-cho, Toyonaka, Osaka 561-0825, Japan
| | - Ikuo Fujii
- School
of Science, Osaka Prefecture University, 1-1 Gakuen-cho,
Naka-ku, Sakai, Osaka 599-8531, Japan
| | - Shin-Ichiro Nishimura
- Faculty
of Advanced Life Science, Hokkaido University, N21, W11, Kita-ku, Sapporo, Hokkaido 001-0021, Japan
| | - Yoshito Numata
- Shionogi
Pharmaceutical Research Center, Shionogi
& Co., Ltd., 3-1-1
Futaba-cho, Toyonaka, Osaka 561-0825, Japan
| |
Collapse
|
25
|
Artigas G, Monteiro JT, Hinou H, Nishimura SI, Lepenies B, Garcia-Martin F. Glycopeptides as Targets for Dendritic Cells: Exploring MUC1 Glycopeptides Binding Profile toward Macrophage Galactose-Type Lectin (MGL) Orthologs. J Med Chem 2017; 60:9012-9021. [PMID: 29045792 DOI: 10.1021/acs.jmedchem.7b01242] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The macrophage galactose-type lectin (MGL) recognizes glycan moieties exposed by pathogens and malignant cells. Particularly, mucin-1 (MUC1) glycoprotein presents an altered glycosylation in several cancers. To estimate the ability of distinct MGL orthologs to recognize aberrant glycan cores in mucins, we applied evanescent-field detection to a versatile MUC1-like glycopeptide microarray platform. Here, as binding was sequence-dependent, we demonstrated that not only sugars but also peptide region impact the recognition of murine MGL1 (mMGL1). In addition, we observed for all three MGL orthologs that divalent glycan presentation increased the binding. To assess the utility of the glycopeptide binders of the MGL orthologs for MGL targeting, we performed uptake assays with fluorescein-MUC1 using murine dendritic cells. A diglycosylated MUC1 peptide was preferentially internalized in an MGL-dependent fashion, thus showing the utility for divalent MGL targeting. These findings may be relevant to a rational design of antitumor vaccines targeting dendritic cells via MGL.
Collapse
Affiliation(s)
- Gerard Artigas
- Faculty of Advanced Life Science and Graduate School of Life Science, Hokkaido University , N21, W11, Kita-ku, 001-0021 Sapporo, Japan
| | - João T Monteiro
- Immunology Unit & Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover , Bünteweg 17, 30559 Hannover, Germany
| | - Hiroshi Hinou
- Faculty of Advanced Life Science and Graduate School of Life Science, Hokkaido University , N21, W11, Kita-ku, 001-0021 Sapporo, Japan.,Medicinal Chemistry Pharmaceuticals, Co., Ltd. N9W15, Chuo-ku, 060-0009 Sapporo, Japan
| | - Shin-Ichiro Nishimura
- Faculty of Advanced Life Science and Graduate School of Life Science, Hokkaido University , N21, W11, Kita-ku, 001-0021 Sapporo, Japan.,Medicinal Chemistry Pharmaceuticals, Co., Ltd. N9W15, Chuo-ku, 060-0009 Sapporo, Japan
| | - Bernd Lepenies
- Immunology Unit & Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover , Bünteweg 17, 30559 Hannover, Germany
| | - Fayna Garcia-Martin
- Faculty of Advanced Life Science and Graduate School of Life Science, Hokkaido University , N21, W11, Kita-ku, 001-0021 Sapporo, Japan
| |
Collapse
|
26
|
Pett C, Cai H, Liu J, Palitzsch B, Schorlemer M, Hartmann S, Stergiou N, Lu M, Kunz H, Schmitt E, Westerlind U. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures. Chemistry 2017; 23:3875-3884. [PMID: 27957769 DOI: 10.1002/chem.201603921] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2016] [Indexed: 01/08/2023]
Abstract
Glycoprotein research is pivotal for vaccine development and biomarker discovery. Many successful methodologies for reliably increasing the antigenicity toward tumor-associated glycopeptide structures have been reported. Deeper insights into the quality and specificity of the raised polyclonal, humoral reactions are often not addressed, despite the fact that an immunological memory, which produces antibodies with cross-reactivity to epitopes exposed on healthy cells, may cause autoimmune diseases. In the current work, three MUC1 antitumor vaccine candidates conjugated with different immune stimulants are evaluated immunologically. For assessment of the influence of the immune stimulant on antibody recognition, a comprehensive library of mucin 1 glycopeptides (>100 entries) is synthesized and employed in antibody microarray profiling; these range from small tumor-associated glycans (TN , STN , and T-antigen structures) to heavily extended O-glycan core structures (type-1 and type-2 elongated core 1-3 tri-, tetra-, and hexasaccharides) glycosylated in variable density at the five different sites of the MUC1 tandem repeat. This is one of the most extensive glycopeptide libraries ever made through total synthesis. On tumor cells, the core 2 β-1,6-N-acetylglucosaminyltransferase-1 (C2GlcNAcT-1) is down-regulated, resulting in lower amounts of the branched core 2 structures, which favor formation of linear core 1 or core 3 structures, and in particular, truncated tumor-associated antigen structures. The core 2 structures are commonly found on healthy cells and the elucidation of antibody cross-reactivity to such epitopes may predict the tumor-selectivity and safety of synthetic vaccines. With the extended mucin core structures in hand, antibody cross-reactivity toward the branched core 2 glycopeptide epitopes is explored. It is observed that the induced antibodies recognize MUC1 peptides with very high glycosylation site specificity. The nature of the antibody response is characteristically different for antibodies directed to glycosylation sites in either the immune-dominant PDTR or the GSTA domain. All antibody sera show high reactivity to the tumor-associated saccharide structures on MUC1. Extensive glycosylation with branched core 2 structures, typically found on healthy cells, abolishes antibody recognition of the antisera and suggests that all vaccine conjugates preferentially induce a tumor-specific humoral immune response.
Collapse
Affiliation(s)
- Christian Pett
- Gesellschaft zur Förderung der Analytischen Wissenschaften e.V. ISAS-Leibniz Institute for Analytical Sciences, Otto-Hahn-Str. 6b, 44227, Dortmund, Germany
| | - Hui Cai
- Gesellschaft zur Förderung der Analytischen Wissenschaften e.V. ISAS-Leibniz Institute for Analytical Sciences, Otto-Hahn-Str. 6b, 44227, Dortmund, Germany
| | - Jia Liu
- Institute for Virology, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
| | - Björn Palitzsch
- Institute of Organic Chemistry, Johannes Gutenberg, University of Mainz, Duesbergweg 10-14, 55128, Mainz, Germany
| | - Manuel Schorlemer
- Gesellschaft zur Förderung der Analytischen Wissenschaften e.V. ISAS-Leibniz Institute for Analytical Sciences, Otto-Hahn-Str. 6b, 44227, Dortmund, Germany
| | - Sebastian Hartmann
- Institute of Organic Chemistry, Johannes Gutenberg, University of Mainz, Duesbergweg 10-14, 55128, Mainz, Germany
| | - Natascha Stergiou
- University Medical Center, Institute of Immunology, Johannes Gutenberg University of Mainz, Langenbeckstr. 1, Geb. 708, 55101, Mainz, Germany
| | - Mengji Lu
- Institute for Virology, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
| | - Horst Kunz
- Institute of Organic Chemistry, Johannes Gutenberg, University of Mainz, Duesbergweg 10-14, 55128, Mainz, Germany
| | - Edgar Schmitt
- University Medical Center, Institute of Immunology, Johannes Gutenberg University of Mainz, Langenbeckstr. 1, Geb. 708, 55101, Mainz, Germany
| | - Ulrika Westerlind
- Gesellschaft zur Förderung der Analytischen Wissenschaften e.V. ISAS-Leibniz Institute for Analytical Sciences, Otto-Hahn-Str. 6b, 44227, Dortmund, Germany
| |
Collapse
|
27
|
Artigas G, Hinou H, Garcia-Martin F, Gabius HJ, Nishimura SI. Synthetic Mucin-Like Glycopeptides as Versatile Tools to Measure Effects of Glycan Structure/Density/Position on the Interaction with Adhesion/Growth-Regulatory Galectins in Arrays. Chem Asian J 2016; 12:159-167. [DOI: 10.1002/asia.201601420] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2016] [Revised: 11/21/2016] [Indexed: 12/15/2022]
Affiliation(s)
- Gerard Artigas
- Faculty of Advanced Life Science; Hokkaido University, N21W11, Kita-ku; Sapporo 001-0021 Japan
| | - Hiroshi Hinou
- Faculty of Advanced Life Science; Hokkaido University, N21W11, Kita-ku; Sapporo 001-0021 Japan
- Medicinal Chemistry Pharmaceuticals, Co., Ltd. N9W15, Chuo-ku; Sapporo 060-0009 Japan
| | - Fayna Garcia-Martin
- Faculty of Advanced Life Science; Hokkaido University, N21W11, Kita-ku; Sapporo 001-0021 Japan
| | - Hans-Joachim Gabius
- Institute of Physiological Chemistry; Faculty of Veterinary Medicine; Ludwig-Maximilians-University Munich; Veterinärstr. 13 80539 München Germany
| | - Shin-Ichiro Nishimura
- Faculty of Advanced Life Science; Hokkaido University, N21W11, Kita-ku; Sapporo 001-0021 Japan
- Medicinal Chemistry Pharmaceuticals, Co., Ltd. N9W15, Chuo-ku; Sapporo 060-0009 Japan
| |
Collapse
|
28
|
Ohyabu N, Kakiya K, Yokoi Y, Hinou H, Nishimura SI. Convergent Solid-Phase Synthesis of Macromolecular MUC1 Models Truly Mimicking Serum Glycoprotein Biomarkers of Interstitial Lung Diseases. J Am Chem Soc 2016; 138:8392-5. [DOI: 10.1021/jacs.6b04973] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Naoki Ohyabu
- Shionogi & Company, Ltd., 3-1-1 Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan
- Graduate School of Life Science and Faculty of Advanced
Life Science, Hokkaido University, N21, W11, Kita-ku, Sapporo 001-0021, Japan
| | - Kiyoshi Kakiya
- Shionogi & Company, Ltd., 2-1-3 Kuiseterashima, Amagasaki 660-0813, Japan
| | - Yasuhiro Yokoi
- Graduate School of Life Science and Faculty of Advanced
Life Science, Hokkaido University, N21, W11, Kita-ku, Sapporo 001-0021, Japan
| | - Hiroshi Hinou
- Graduate School of Life Science and Faculty of Advanced
Life Science, Hokkaido University, N21, W11, Kita-ku, Sapporo 001-0021, Japan
- Medicinal Chemistry Pharmaceuticals, Co., Ltd., N21, W12, Kita-ku, Sapporo 001-0022, Japan
| | - Shin-Ichiro Nishimura
- Graduate School of Life Science and Faculty of Advanced
Life Science, Hokkaido University, N21, W11, Kita-ku, Sapporo 001-0021, Japan
- Medicinal Chemistry Pharmaceuticals, Co., Ltd., N21, W12, Kita-ku, Sapporo 001-0022, Japan
| |
Collapse
|